Drug Hypersensitivity
22
2
2
16
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.6%
3 terminated out of 22 trials
84.2%
-2.3% vs benchmark
5%
1 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (22)
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Establishment of a Registry for Immediate Drug Allergy
Turkish Version of the Parent-Reported Drug Hypersensitivity Quality of Life Questionnaire
Optimal Doses for Drug Provocation Tests to Beta-lactams
Management of Drug Hypersensitivity in Children
An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community
Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
Drug Allergy Labels After Drug Allergy Investigation
Medical Device for Drug Allergy Diagnosis
Drug Challenges Without Prior Skin Testing
Cephalosporin Hypersensitivity
Drug Provocation Test (DPT) to Paracetamol
Drug Provocation Test (DPT) to Non Steroidal Anti-inflammatory Drugs (NSAID)
Allergy Testing of Patients Labeled as Penicillin Allergic
Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Predictive Models for Betalactam Allergy
Negative Predictive Value of Drug Provocation Tests to Beta-lactams
Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)